Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
531. |
ECCT/22/05/01 | VICTORION-2 PREVENT A randomized, double-blind, placebo-controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease |
Principal Investigator(s) 1. Anthony Gikonyo 2. ELIJAH SAMMY NYAINDA OGOLA Site(s) in Kenya 1. The Karen Hospital (Nairobi City county) 2. Centre for research in Therapeutic Sciences (CREATES (Nairobi City county) |
05-10-2022 |
View |
532. |
ECCT/15/11/05 | FALCI Study A Randomized, Double-blind, Phase IIb Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Regimen of Ferroquine (FQ) with Artefenomel (OZ439) in Adults and Children with Uncomplicated Plasmodium falciparum Malaria. |
Principal Investigator(s) 1. Grace Kiringa Kaguthi Site(s) in Kenya 1. KEMRI Center for Respiratory Diseases Research (Siaya county) 2. KEMRI Walter Reed Kombewa (Kisumu county) 3. KEMRI Kisumu (Kisumu county) |
01-02-2016 |
View |
533. |
ECCT/20/07/02 | RV 460 HIV Vaccine Trial A Randomized, Double-Blind Phase 1 Trial to Evaluate the Safety and Immunogenicity of Priming with Env-C Plasmid DNA Vaccine Alone, with Different Adjuvants, or with an Adjuvanted HIV Env gp145 C.6980 Protein Vaccine and Boosting with the Adjuvanted HIV Env gp145 C.6980 Protein Vaccine with or without the Env-C Plasmid DNA Vaccine in Healthy HIV Uninfected Adults in Kenya |
Principal Investigator(s) 1. Josphat Kosgei Site(s) in Kenya KEMRI/US MRDA-A/K, KERICHO |
19-10-2020 |
View |
534. |
ECCT/09/06/02 | A Randomized Trial to Evaluate the Effectiveness of Antiretroviral Therapy plus HIV Primary Care versus HIV Primary Care Alone to Prevent the Sexual Transmission of HIV-1 In Serodiscordant Couples |
Principal Investigator(s) 1. Lisa Ann Mills Site(s) in Kenya Kisumu, Kenya |
05-07-2012 |
View |
535. |
ECCT/15/11/01 | A5264 A Randomized Evaluation of Antiretroviral Therapy Alone or with Delayed Chemotherapy versus Antiretroviral Therapy with Immediate Adjunctive Chemotherapy for Treatment of Limited Stage AIDS-KS in Resource-Limited Settings (REACT-KS) |
Principal Investigator(s) 1. Dr. Victor Otieno Mudhune Site(s) in Kenya 1. KEMRI CDC (Kisumu county) |
05-05-2016 |
View |
536. |
ECCT/23/10/01 | CROSSWALK Chronic (C) A RANDOMIZED DOUBLE-BLIND PHASE IIA STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB AS ADJUNCT TREATMENT IN PREVENTION OF VASO-OCCLUSIVE EPISODES (VOE) IN SICKLE CELL DISEASE (SCD) (CROSSWALK-c) |
Principal Investigator(s) 1. Fredrick Chite Asirwa 2. Doreen Terry Karimi Site(s) in Kenya 1. Gertrudes Childrens Hospital (Nairobi City county) 2. International Cancer Institute (Uasin Gishu county) |
10-01-2024 |
View |
537. |
ECCT/19/03/05 | EPI-MAL-003 (Siaya) A prospective study to evaluate the safety, effectiveness and impact of the RTS,S/AS01E vaccine in young children in sub-Saharan Africa (v1.0 11Oct2017): Site-specific protocol for Siaya County, western Kenya |
Principal Investigator(s) 1. Simon Kariuki 2. Martina Oneko Site(s) in Kenya 1. Bondo sub-county (Siaya county) 2. Gem sub-county (Siaya county) |
17-05-2019 |
View |
538. |
ECCT/22/03/07 | ELEVATUM A PHASE IIIB/IV, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE FARICIMAB (RO6867461) TREATMENT RESPONSE IN TREATMENT-NAÏVE, UNDERREPRESENTED PATIENTS WITH DIABETIC MACULAR EDEMA |
Principal Investigator(s) 1. Dr. Oscar Muwale Onyango 2. Dr. Muchai Gachago Site(s) in Kenya 1. The Nairobi Hospital (Nairobi City county) 2. City Eye Hospital (Nairobi City county) |
05-09-2022 |
View |
539. |
ECCT/23/01/01 | PROHER A PHASE IIIB, MULTINATIONAL, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE PATIENT PREFERENCE FOR HOME ADMINISTRATION OF FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB FOR SUBCUTANEOUS ADMINISTRATION IN PARTICIPANTS WITH EARLY OR LOCALLY ADVANCED/ INFLAMMATORY HER2-POSITIVE BREAST CANCER |
Principal Investigator(s) 1. Fredrick Chite Asirwa 2. Mansoor Saleh Site(s) in Kenya 1. Aga Khan University, Nairobi (Nairobi City county) 2. International Cancer Institute (Uasin Gishu county) |
12-05-2023 |
View |
540. |
ECCT/22/12/03 | heredERA A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO + TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER |
Principal Investigator(s) 1. Mansoor Saleh 2. Fredrick Chite Asirwa Site(s) in Kenya 1. Aga Khan University, Nairobi (Nairobi City county) 2. International Cancer Institute (Uasin Gishu county) |
12-04-2023 |
View |